GLP-1s Aren't "Skinny Shots": Retatrutide, CKM & the Future of Obesity Care

GLP-1 medications have become some of the most talked about drugs in medicine—but are they really just "skinny shots"?In this episode of Weight & Measure with Mike and Zach, we sit down with two of the most respected voices in obesity care to separate fact from fiction and explore where obesity treatment is heading next.Joining us are:Ted Kyle, RPh, MBA – Founder of ConscienHealth and one of the nation's leading advocates for evidence-based obesity policy and public education.Katherine Saunders, MD, DABOM – Obesity Medicine physician and nationally recognized expert on GLP-1 medications, emerging obesity therapies, and comprehensive obesity care.Together, we discuss why GLP-1 medications are changing much more than body weight, how obesity medicine is shifting its focus toward overall health, and why the next generation of therapies—including retatrutide—could reshape obesity treatment once again.• Why calling GLP-1s "skinny shots" misses the bigger picture.• How GLP-1 medications are changing healthcare, society, and the conversation around obesity.• Why obesity is a chronic disease—and why that idea still faces resistance.• What CKM (Cardiovascular, Kidney, and Metabolic Health) means and why it's becoming a new framework for treating patients.• The latest research on access to obesity care and what the "secret shopper" study revealed.• How social media has influenced public understanding of obesity, for better and for worse.• The science behind glucagon agonists, amylin agonists, and combination therapies.• Why retatrutide has generated so much excitement—and why experts caution that more weight loss doesn't automatically mean a better medication.• How GLP-1 medications fit alongside metabolic and bariatric surgery as part of comprehensive, individualized obesity care.• What today's obesity experts hope we'll understand differently about GLP-1s twenty years from now.Whether you're living with obesity, taking a GLP-1 medication, considering metabolic and bariatric surgery, following the latest research on retatrutide, or simply trying to better understand obesity as a chronic disease, this conversation provides practical, evidence-based insights grounded in science—not stigma.• Ted Kyle, RPh, MBA• Katherine Saunders, MD, DABOMGLP-1 • GLP-1 medications • Retatrutide • Tirzepatide • Semaglutide • Ozempic • Wegovy • Mounjaro • Zepbound • Obesity Medicine • Obesity Care • Chronic Disease • CKM • Cardiovascular Kidney Metabolic Health • Metabolic and Bariatric Surgery • Weight Loss Medications • Anti-Obesity Medications • Emerging Obesity Therapies • Glucagon Agonists • Amylin Agonists • Comprehensive Obesity Care • Weight Bias • Obesity Advocacy • Patient Advocacy • Evidence-Based MedicineIf you enjoyed this conversation, be sure to subscribe to Weight & Measure on YouTube and follow us on Spotify, Apple Podcasts, and Amazon Music so you never miss future conversations exploring the science of obesity, GLP-1 medications, metabolic and bariatric surgery, and the future of evidence-based obesity care.More Science. Less Stigma.